Current and historical daily PE Ratio for AbbVie Inc (
) from 2012 to Oct 04 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. AbbVie stock (ABBV) PE ratio as of Oct 04 2023 is 30.39.
More Details
AbbVie Inc (ABBV) PE Ratio (TTM) Chart
AbbVie Inc (ABBV) PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Total 1200
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| AbbVie PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2023-10-05 | 30.4 | 2023-08-01 | 30.6 |
| 2023-10-03 | 30.3 | 2023-07-31 | 30.8 |
| 2023-10-02 | 30.5 | 2023-07-28 | 31.0 |
| 2023-09-29 | 30.7 | 2023-07-27 | 30.6 |
| 2023-09-28 | 31.3 | 2023-07-26 | 29.2 |
| 2023-09-27 | 31.5 | 2023-07-25 | 29.1 |
| 2023-09-26 | 31.7 | 2023-07-24 | 29.5 |
| 2023-09-25 | 31.8 | 2023-07-21 | 29.6 |
| 2023-09-22 | 31.4 | 2023-07-20 | 29.3 |
| 2023-09-21 | 31.6 | 2023-07-19 | 28.3 |
| 2023-09-20 | 31.6 | 2023-07-18 | 28.1 |
| 2023-09-19 | 31.6 | 2023-07-17 | 27.7 |
| 2023-09-18 | 31.7 | 2023-07-14 | 28.0 |
| 2023-09-15 | 31.3 | 2023-07-13 | 27.5 |
| 2023-09-14 | 31.6 | 2023-07-12 | 27.8 |
| 2023-09-13 | 31.1 | 2023-07-11 | 27.9 |
| 2023-09-12 | 30.7 | 2023-07-10 | 27.7 |
| 2023-09-11 | 30.7 | 2023-07-07 | 27.9 |
| 2023-09-08 | 30.7 | 2023-07-06 | 28.2 |
| 2023-09-07 | 30.6 | 2023-07-05 | 28.3 |
| 2023-09-06 | 30.0 | 2023-07-03 | 27.8 |
| 2023-09-05 | 30.1 | 2023-06-30 | 27.7 |
| 2023-09-01 | 30.5 | 2023-06-29 | 27.4 |
| 2023-08-31 | 30.2 | 2023-06-28 | 27.3 |
| 2023-08-30 | 30.5 | 2023-06-27 | 31.4 |
| 2023-08-29 | 30.4 | 2023-06-26 | 31.9 |
| 2023-08-28 | 30.3 | 2023-06-23 | 32.1 |
| 2023-08-25 | 30.2 | 2023-06-22 | 32.5 |
| 2023-08-24 | 30.2 | 2023-06-21 | 32.4 |
| 2023-08-23 | 30.3 | 2023-06-20 | 32.6 |
| 2023-08-22 | 30.5 | 2023-06-16 | 32.8 |
| 2023-08-21 | 30.9 | 2023-06-15 | 32.1 |
| 2023-08-18 | 30.9 | 2023-06-14 | 32.2 |
| 2023-08-17 | 30.9 | 2023-06-13 | 32.7 |
| 2023-08-16 | 31.2 | 2023-06-12 | 32.6 |
| 2023-08-15 | 31.3 | 2023-06-09 | 32.7 |
| 2023-08-14 | 31.3 | 2023-06-08 | 32.5 |
| 2023-08-11 | 31.3 | 2023-06-07 | 32.3 |
| 2023-08-10 | 31.2 | 2023-06-06 | 32.0 |
| 2023-08-09 | 31.0 | 2023-06-05 | 32.4 |
| 2023-08-08 | 30.8 | 2023-06-02 | 32.4 |
| 2023-08-07 | 30.9 | 2023-06-01 | 31.6 |
| 2023-08-04 | 30.4 | 2023-05-31 | 32.6 |
| 2023-08-03 | 30.7 | 2023-05-30 | 32.3 |
| 2023-08-02 | 30.7 | 2023-05-26 | 32.5 |
AbbVie Inc (ABBV) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
AbbVie Inc
NAICS : 325412
SIC : 5122
ISIN : US00287Y1091
Share Class Description:
ABBV: Ordinary SharesCompare
Compare
Traded in other countries / regions
ABBV.USA0QCV.UKABBV.CanadaABBV34.BrazilABBV.Mexico4AB.GermanyABBV.AustriaABBV.SwitzerlandABBV.France IPO Date
2012-12-10Description
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers